CORALVILLE, Iowa, Jan. 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at “The MoneyShow Orlando,” one of the largest annual retail investor conferences held in the U.S. The conference will take place at the Omni Orlando Resort ChampionsGate, February 8-11, 2018.
Dr. Mickle will deliver a strategic presentation on the opportunities and outlook for KemPharm’s prodrug development platform, utilizing the company’s proprietary LAT™ (Ligand Activated Therapy) platform.
KemPharm at The MoneyShow Orlando, February 8-11, 2018:
Venue: Omni Orlando Resort ChampionsGate, 1500 Masters Blvd, ChampionsGate, FL 33896
Presentation: Friday, February 9th at 1:30 p.m. ET
Booth Location: #213 on the Exhibit Floor
A copy of the presentation will be made available within the Investor Relations section of KemPharm’s website at: www.KemPharm.com
MoneyShow - Invest Smarter, Trade Wiser is a global network of investment and trading expert education. The privately held financial media company was founded in 1981 and is headquartered in Sarasota, Florida, USA. For more information, visit www.moneyshow.com.
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) platform technology. KemPharm utilizes its proprietary LATTM platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the treatment of ADHD. In addition, the company is advancing Apadaz™, an immediate-release, abuse-deterrent hydrocodone/acetaminophen combination product candidate, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Caution Concerning Forward Looking Statements:
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm’s business are described in detail in KemPharm's Annual Report on Form 10-K for the year ended December 31, 2016, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.